Curriculum Vitae
Research Interest
Dr. Kobashigawa is Clinical Professor of
Medicine in the David Geffen School of Medicine at the University of
California, Los Angeles (UCLA) and the Medical Director of the Heart
Transplant Program.
Dr. Kobashigawa is recognized
internationally as a leader in the heart transplant field. He has
served as the past Chairman of the American College of Cardiology
Committee on Heart Failure and Transplantation, and as the past
president of the International Society of Heart and Lung
Transplantation.
Dr. Kobashigawa’s interests include:
Statins, intravascular ultrasound, newer immunosuppression clinical
trials, and exercise physiology of the denervated donor heart in
heart transplant patients.
Representative
Publications
Kobashigawa JA, Miller LW,
Russell SD, Ewald GA, Zucker MJ, Goldberg LR, Eisen HJ, Salm K,
Tolzman D, Gao J, Fitzsimmons W, First R; Study Investigators.
Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs.
cyclosporine with MMF in cardiac transplant patients: 1-year report.
Am J Transplant. 2006 Jun;6(6):1377-86.
Kobashigawa JA, Tobis JM, Mentzer
RM, Valantine HA, Bourge RC, Mehra MR, Smart FW, Miller LW, Tanaka
K, Li H, Gjertson DW, Gordon RD. Mycophenolate mofetil reduces
intimal thickness by intravascular ultrasound after heart
transplant: reanalysis of the multicenter trial. Am J Transplant.
2006 May;6(5 Pt 1):993-7.
Kobashigawa JA, Patel JK.
Immunosuppression for heart transplantation: where are we now? Nat
Clin Pract Cardiovasc Med. 2006 Apr;3(4):203-12.
Kobashigawa JA, Patel J, Furukawa
H, Moriguchi JD, Yeatman L, Takemoto S, Marquez A, Shaw J, Oeser BT,
Subherwal S, Wu GW, Kawano J, Laks H. Five-year results of a
randomized, single-center study of tacrolimus vs microemulsion
cyclosporine in heart transplant patients. J Heart Lung Transplant.
2006 Apr;25(4):434-9.
Kobashigawa JA, Moriguchi JD,
Laks H, Wener L, Hage A, Hamilton MA, Cogert G, Marquez A,
Vassilakis ME, Patel J, Yeatman L. Ten-year follow-up of a
randomized trial of pravastatin in heart transplant patients. J
Heart Lung Transplant. 2005 Nov;24(11):1736-40.
Eisen HJ, Tuzcu EM, Dorent R,
Kobashigawa J, Mancini D, Valantine-von Kaeppler HA, Starling
RC, Sorensen K, Hummel M, Lind JM, Abeywickrama KH, Bernhardt P; RAD
B253 Study Group. Everolimus for the prevention of allograft
rejection and vasculopathy in cardiac-transplant recipients. N Engl
J Med. 2003 Aug 28;349(9):847-58.
Laks H, Marelli D, Fonarow GC, Hamilton
MA, Ardehali A, Moriguchi JD, Bresson J, Gjertson D, Kobashigawa
JA; UCLA Heart Tranplant Group. Use of two recipient lists for
adults requiring heart transplantation. J Thorac Cardiovasc Surg.
2003 Jan;125(1):49-59.
Kobashigawa JA, Renlund DG,
Gerosa G, Almenar, Eisen HJ, Keogh AM, Lehmkuhl HB, Livi U, Ross H,
Segovia J, Yonan, Novartis Reps. A 12 month, single blind,
randomized, parallel group, multicenter study, to investigate the
efficacy and safety of enteric coated mycophenolate sodium (EC-MPS)
compared with mycophenolate mofetil (MMF) in de novo heart
recipients: 12 month results. J Heart Lung Transplant 2006.
(In Press)
Kobashigawa, JA. Cardiac
Allograft Vasculopathy in Heart Transplant Patients: Pathologic and
Clinical Aspects for Angioplasty/Stenting. Editorial Comment. J Am
Coll Cardiol 2006. (In Press) |
